96786 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses RNA viruses
Sub-classes:VIRUS-LIKE PARTICLES FOR PREVENTING THE SPREADING AND LOWERING THE INFECTION RATE OF VIRUSES
#2ARTIFICIAL VIRAL CAPSID
#3PEPTIDE COMPOUNDS TO REGULATE THE COMPLEMENT SYSTEM
#4RECOMBINANT HVT VECTORS EXPRESSING MULTIPLE ANTIGENS OF AVIAN PATHOGENS AND USES THEREOF
#5PREFUSION-STABILIZED HMPV F PROTEINS
#6HEPATITIS E VIRUS-LIKE PARTICLES (VLPS) DERIVED FROM CONSENSUS SEQUENCES
#7METHODS OF TARGETED DELIVERY TO A HOST USING A CARRIER
#8PEPTIDE COMPOUNDS TO REGULATE THE COMPLEMENT SYSTEM
#9COMPOSITIONS AND METHODS FOR PREVENTION OF PISCINE MYOCARDITIS
#10CARRIER FOR LOWERING THE INFECTION RATE OF BACTERIA
#11Methods of fabricating carriers for targeted delivery to a host
#12VACCINE CANDIDATES FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) HAVING ATTENUATED PHENOTYPES
#13Prefusion-stabilized hMPV F proteins
#14PEPTIDE COMPOUNDS TO REGULATE THE COMPLEMENT SYSTEM
#15TOMATO PLANT RESISTANT TO TOMATO BROWN RUGOSE FRUIT VIRUS
#16CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS
#17LASSA VIRUS VACCINE AND USES THEREOF
#18PEPTIDES AND METHODS OF USE
#19Scaffolds For Inducing Antibody Responses Against Antigenic Sites
#20Methods and composition for gene delivery using an engineered viral particle
#21Carrier for targeted delivery to a host
#22Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses
#23Prefusion-stabilized hMPV F proteins
#24LASSA VIRUS VACCINE AND USES THEREOF
#25VLP-based bivalent Ebola vaccines and methods of making and using same
#26ANTIVIRAL STRUCTURALLY-STABILIZED EBOLAVIRUS PEPTIDES AND USES THEREOF
#27Prefusion-stabilized hMPV F proteins
#28ENGINEERED ARENAVIRUS GLYCOPROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
#29RECOMBINANT HVT VECTORS EXPRESSING MULTIPLE ANTIGENS OF AVIAN PATHOGENS AND USES THEREOF
#30Virus-like particles for preventing the spreading and lowering the infection rate of viruses
#31PEPTIDE COMPOUNDS TO REGULATE THE COMPLEMENT SYSTEM
#32LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) ANALYSIS FOR PATHOGENIC TARGETS
#33CELL LINE AND PRODUCING METHOD THEREOF
#34Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
#35Methods and composition for gene delivery using an engineered viral particle
#36METHODS FOR LOWERING THE INFECTION RATE OF VIRUSES
#37Virus-like particles for preventing the spreading and lowering the infection rate of viruses
#38Tomato plant resistant to Tomato Brown Rugose Fruit Virus
#39PEPTIDE COMPOUNDS TO REGULATE THE COMPLEMENT SYSTEM
#40Chimpanzee adenoviral vector-based filovirus vaccines
#41USE OF LIGANDS DERIVED FROM RECEPTOR-BINDING DOMAIN OF PORCINE ENDOGENOUS RETROVIRUS TYPE B FOR DIAGNOSING SMVT-RELATED DISEASES
#42VLP-based bivalent ebola vaccines and methods of making and using same
#43COMPOSITIONS AND METHODS FOR REGULATING GENE EXPRESSION FOR TARGETED MUTAGENESIS
#44PEPTIDE COMPOUNDS TO REGULATE THE COMPLEMENT SYSTEM
#45Methods and composition for gene delivery using an engineered viral particle
#46Tomato plant resistant to tomato brown rugose fruit virus
#47Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses
#48RECOMBINANT NEWCASTLE DISEASE VIRUSES AND USES THEREOF FOR THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS DISEASE
#49Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
#50TARGETED GENE ACTIVATION USING MODIFIED GUIDE RNA
#51Cyclic peptides for protection against respiratory syncytial virus
#52Optically controlled virus protein, gene thereof, and virus vector containing said gene
#53PEPTIDE COMPOUNDS TO REGULATE THE COMPLEMENT SYSTEM
#54Recombinant HVT vectors expressing multiple antigens of avian pathogens and uses thereof
#55Multi-functional peptides and use thereof
#56METHOD OF ENHANCING RNA EXPRESSION IN A CELL
#57Anti-HERV-K envelope protein antibodies and methods for detecting HERV-K envelope protein in patients with sporadic amyotrophic lateral sclerosis
#58Multivalent recombinant modified vaccinia virus ankara (MVA) vector encoding filovirus immunogens
#59Engineering Virus-like Nanocarriers for Biomolecule Delivery
#60VLP-BASED MONOVALENT EBOLA VACCINES AND METHODS OF MAKING AND USING SAME
#61VLP-based bivalent Ebola vaccines and methods of making and using same
#62Epizootic hemorrhagic disease vaccine
#63Peptide compounds to regulate the complement system
#64GENOME EDITING KIT
#65Compositions and methods for treating arenavirus infection
#66Recombinant HVT vectors expressing multiple antigens of avian pathogens and uses thereof
#67Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes
#68Assays for detecting antibodies capable of mediating antibody-dependent cell-mediated cytotoxicity
#69Treatment of canine atopic dermatitis
#70Compositions and methods for regulating gene expression for targeted mutagenesis
#71Norovirus derived immunogenic compositions and methods
#72Feline calicivirus vaccine
#73Peptide compounds to regulate the complement system
#74Viral chimeric particle of potato virus X and use thereof for in vitro diagnosis of Sjögren syndrome
#75Recombinant HVT vectors expressing multiple antigens of avian pathogens and uses thereof
#76Viral RNA segments as immunomodulatory agents and vaccine components
#77Methods and compositions for treating cancer
#78Vaccine for use in protecting a pig against porcine epidemic diarrhea virus
#79Recombinant modified vaccinia virus Ankara (MVA) multivalent filovirus immunogenic compositions and methods of use
#80Construct for the delivery of a molecule into the cytoplasm of a cell
#81Ebolavirus pre-hairpin intermediate mimics and methods of use
#82Identification and attenuation of the immunosuppressive domains in fusion proteins of enveloped RNA viruses
#83Peptide compounds to regulate the complement system
#84Norovirus derived immunogenic compositions and methods
#85Peptide compounds to regulate the complement system
#86Pathogenic phlebovirus isolates and compositions and methods of use
#87Arenavirus inhibiting peptides and uses therefor
#88Membrane protein expression vector comprising major envelope protein P9 of systovirus PHI12 as a fusion partner and method for producing membrane protein using the same
#89Peptide compounds to regulate the complement system
#90SPHERICAL NANO AND MICROPARTICLES DERIVED FROM PLANT VIRUSES FOR THE DISPLAY OF FOREIGN PROTEINS OR EPITOPES
#91Nucleic acid construct containing a nucleic acid derived from the genome of hepatitis C virus (HCV) of genotype 2a, and a cell having such nucleic acid construct introduced therein
#92PARAPOXVIRUS EXPRESSING THE VP60 MAJOR CAPSID PROTEIN OF THE RABBIT HAEMORRHAGIC DISEASE VIRUS
#93NOROVIRUS DERIVED IMMUNOGENIC COMPOSITIONS AND METHODS
#94COMPOSITIONS AND METHODS FOR RE-PROGRAMMING CELLS WITHOUT GENETIC MODIFICATION FOR TREATMENT OF NEUROLOGICAL DISORDERS
#95Nucleic acid construct containing a nucleic acid derived from the genome of hepatitis C virus (HCV) of genotype 2a, and a cell having such nucleic acid construct introduced therein
#96Nucleic acid construct containing a nucleic acid derived from the genome of hepatitis C virus (HCV) of genotype 2A, and a cell having such nucleic acid construct introduced therein
#97Systems and methods for generating immune responses in subjects using microchannel delivery devices